Brief: Compass Therapeutics Reports Positive Interim Phase 2 Data Of Ctx-009

Compass Therapeutics

04/05/2022 14:33

May 4 (Reuters) - Compass Therapeutics Inc.  CMPX.O :
    * COMPASS THERAPEUTICS REPORTS POSITIVE INTERIM PHASE 2 DATA
OF
CTX-009 IN COMBINATION WITH PACLITAXEL IN BILIARY TRACT CANCERS
    * COMPASS THERAPEUTICS INC. - CTX-009 DEMONSTRATED A 42%
OVERALL
RESPONSE RATE (ORR) BASED ON 10 PARTIAL RESPONSES (PRS) IN 24
ENROLLED PATIENTS
    * COMPASS THERAPEUTICS INC. - CTX-009 CONTINUES TO BE WELL
TOLERATED, CONSISTENT WITH PHASE 1 STUDIES
    * COMPASS THERAPEUTICS INC. - COMPASS PLANS TO INITIATE
STAGE 2 OF
PHASE 2 STUDY IN U.S. IN Q3 2022

Source text for Eikon:  ID:nGNX3qXm3Q 
Further company coverage:  CMPX.O 

 ((reuters.briefs@thomsonreuters.com;))